Pasithea Therapeutics expands PAS-004 Phase 1/1b NF1 trial with higher dose cohorts

Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp.

KTTA

0.00
  • Pasithea amended its Phase 1/1b trial protocol for PAS-004 in NF1 patients with plexiform neurofibroma, expanding dose escalation.
  • Interim NF1 data were not presented; an update remains scheduled for Q4 2026.
  • Changes aim to broaden dosing experience, extend treatment duration, improve imaging and skin tumor assessments to support dose selection.
  • Enrollment and multi-cycle dosing completed for initial cohorts; 18 patients dosed in Part A, with 24 mg and an intermediate 15 mg cohort enrolled.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160700PRIMZONEFULLFEED9747505) on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.